Connexion
E-mail
Mot de passe
Afficher le mot de passe
Retenir
Mot de passe oublié ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 
OFFON

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
  Rapport
SynthèseCotationsGraphiquesActualitésNotationsAgendaSociétéFinancesConsensusRévisionsDérivésFondsCommunauté 
SynthèseToute l'actualitéReco analystesAutres languesCommuniquésPublications officiellesActualités du secteur
Actualités dans d'autres langues sur BRISTOL-MYERS SQUIBB COMPANY
15/10BRISTOL MYERS SQUIBB : Says Zeposia Gets Positive Recommendation From CHMP for Ulcerative ..
15/10BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatmen..
15/10Bristol Myers Squibb Gets CHMP Backing for Zeposia in Ulcerative Colitis
13/10MS-behandeling Bristol-Myers Squibb lang werkzaam en veilig
13/10BRISTOL MYERS SQUIBB : Announces Up to Five Years of Data from Long-Term DAYBREAK Study Re..
13/10Bristol-Myers Squibb Company Announces Interim Results from the Phase 3 Open-Label Exte..
12/10AGENUS : to Receive $20 Million Payment from Bristol Myers Squibb for AGEN1777; Shares Up ..
11/10EVOTEC : expands neuroscience collaboration with Bristol Myers Squibb to include novel cel..
11/10EVOTEC : LUMITOS AG - Evotec expands neuroscience collaboration with Bristol Myers Squibb ..
08/10Evotec erweitert Neurologie-Kooperation mit Bristol Myers Squibb
08/10BRISTOL MYERS SHAREHOLDER ALERT BY F : Kahn Swick & Foti, LLC Reminds Investors With Losse..
07/10BRISTOL MYERS SQUIBB : Ulcerative Colitis Therapy Fails to Meet Phase 2 Trial Main Goal - ..
07/10BRISTOL MYERS SQUIBB : Provides Update on Phase 2 Study of Deucravacitinib in Patients Wit..
07/10Bristol Myers Squibb Provides Update on Phase 2 Study of Deucravacitinib in Patients wi..
07/10BRISTOL MYERS : Deucravacitinib Study to Treat Ulcerative Colitis Study Misses Efficacy Ob..
07/10BRISTOL MYERS SQUIBB : Faces Class Action Complaint in Connection With $74 Billion Celgene..
07/10ENTWISTLE & CAPPUCCI : LLP Files a Securities Class Action Complaint Against Bristol-Myers..
04/10BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb's Applicat..
04/10BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb's Applicat..
04/10BRISTOL MYERS SQUIBB : to Hold Investor Event on November 16
01/10BRISTOL MYERS : EMA Validates Relatlimab/Opdivo Combo Application in Melanoma
01/10BRISTOL MYERS SQUIBB : Application of Combination Drug for Initial Cancer Therapy Validate..
01/10BRISTOL MYERS SQUIBB : to Hold Investor Event on November 16
01/10BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb's Applicat..
01/10BRISTOL MYERS SQUIBB : European Medicines Agency Validates Bristol Myers Squibb's Applicat..
01/10European Medicines Agency Validates Bristol Myers Squibb’s Application for Mavacamten f..
30/09BRISTOL MYERS SQUIBB : Data at the EADV 30th Anniversary Congress Highlight the Growing Bo..
30/09Bristol Myers Squibb Announces the Data from 19 Company-Sponsored Scientific Presentati..
27/09BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Ap..
27/09BRISTOL MYERS SQUIBB : FDA Accepts Bristol-Myers Squibb's Supplemental Biologics License A..
27/09U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdiv..
27/09BRISTOL MYERS SQUIBB : FDA to Review Opdivo Combos in Esophageal Squamous Cell Carcinoma
20/09BRISTOL MYERS SQUIBB : FDA Grants Bristol-Myers Squibb Priority Review for Metastatic Mela..
20/09BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
20/09Bristol Myers Squibb Announces FDA Accepts for Priority Review Biologics License Applic..
20/09Bristol Myers Gets FDA Priority Review of Relatlimab/Opdivo Combo in Melanoma
17/09BRISTOL MYERS SQUIBB : Combination Therapy Gets EMA Committee's Backing for Treating Gastr..
17/09BRISTOL MYERS SQUIBB : Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherap..
17/09Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo with Chemotherapy for Pa..
17/09Bristol Myers Gets Positive CHMP Opinion for Opdivo in Gastric, Esophageal Cancers
16/09Bristol-Myers Squibb Down Nine Consecutive Days, on Pace for Longest Losing Streak Sinc..
16/09BRISTOL MYERS SQUIBB : Reports Data From Phase 3 Trial of Opdivo, Yervoy Combination
16/09BRISTOL MYERS SQUIBB : Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yer..
16/09Bristol Myers Squibb Announces Five-Year Data from Checkmate -214 Show Opdivo Plus Yerv..
16/09EXELIXIS : Says New Exploratory Data from Late-Stage Trial Show Potential of Kidney Cancer..
13/09BRISTOL MYERS SQUIBB : Says Phase 3 Trial of Opdivo Combined With Yervoy for Organ Tissue ..
13/09BRISTOL MYERS SQUIBB : According to New Multinational Survey, Healthcare Providers Believe..
13/09BRISTOL MYERS SQUIBB : Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Durable Ov..
13/09Bristol-Myers Squibb Company Announces Three-Year Data from the Checkmate -743
13/09TreeFrog Therapeutics announced that it has received €64 million in funding from Bpifra..
11/09BRISTOL MYERS SQUIBB : Shares Research Supporting Correlation Between New York Heart Assoc..
09/09BRISTOL MYERS SQUIBB : Maintains Cash Dividend at $0.49 per common share, payable on Nov. ..
09/09BRISTOL MYERS SQUIBB : Announces Dividend
09/09Bristol Myers Squibb Announces Quarterly Dividend, Payable on November 1, 2021
08/09BOLT BIOTHERAPEUTICS : Bristol Myers Squibb to Study Combo Therapy for HER2-Expressing Sol..
08/09BRISTOL MYERS SQUIBB : Bolt Biotherapeutics Announces Clinical Collaboration with Bristol ..
08/09Bolt Biotherapeutics Announces Clinical Collaboration with Bristol Myers Squibb to Stud..
08/09BRISTOL MYERS SQUIBB : to Report Results for Third Quarter 2021 on October 27, 2021
08/09BRISTOL MYERS SQUIBB : More than 230 Bristol Myers Squibb Employees Pedal Across the U.S. ..
08/09BRISTOL MYERS SQUIBB : Research at ESMO 2021 Demonstrates Clinical Benefits of Immunothera..
07/09Pharma-Industrie geht von ausreichend Corona-Impfstoff für alle aus
07/09UPDATED STATEMENT : Bristol Myers Squibb on Coronavirus (COVID-19)
07/09BRISTOL MYERS SQUIBB : to Take Part in Morgan Stanley 19th Annual Global Healthcare Confer..
03/09BRISTOL MYERS SQUIBB : Pfizer Alliance is pleased with the decision by the U.S. Court of A..
03/09BRISTOL MYERS SQUIBB : Appeals Court Rules in Favor of Bristol-Myers Squibb in Eliquis Pat..
03/09NOVARTIS' : Sandoz Canada Launches Generic Version of Bristol Myers' Blood Cancer Drug Rev..
02/09Evotec erhält weitere Meilensteinzahlung von Bristol-Myers Squibb
02/09Bristol Myers zieht Option für Lizenzvereinbarung mit Evotec
27/08BRISTOL MYERS SQUIBB : Sixth Circuit Limits Exercise Of Personal Jurisdiction In FLSA Coll..
26/08MARKET CHATTER : US Appeals Court Overturns $1.2 Billion Verdict Against Gilead Sciences, ..
25/08Cardior Pharmaceuticals GmbH announced that it has received €64 million in funding from..
23/08BRISTOL MYERS SQUIBB : Says FDA Accepts Supplemental Biologics License Application for Acu..
23/08BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Review Brist..
23/08Bristol-Myers Squibb Company Announces U.S. Food and Drug Administration Accepts for Pr..
23/08Bristol Myers Gets FDA Priority Review of Orencia in Acute Graft-Vs-Host Disease
1  2  3  4  5  6  7  8  9  10Suiv.
Prochain événement sur BRISTOL-MYERS SQUIBB COMPANY